On the other hand, folate–miR-34a inhibited cell proliferation in breast, cervical, and ovarian cancer cells that highly express FOLR1, indicating its potential therapeutic applications for these FOLR1-expressing cancers. This evidence concerns the gene FOLR1 and ovarian cancer.